PSG Stock Overview
PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
PharmaSGP Holding SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €18.70 |
| 52 Week High | €29.60 |
| 52 Week Low | €17.70 |
| Beta | -0.026 |
| 1 Month Change | -6.50% |
| 3 Month Change | -20.76% |
| 1 Year Change | -26.67% |
| 3 Year Change | -15.77% |
| 5 Year Change | n/a |
| Change since IPO | -45.80% |
Recent News & Updates
Recent updates
PharmaSGP Holding SE Just Beat Revenue Estimates By 25%
Dec 02
One Analyst Just Shaved Their PharmaSGP Holding SE (ETR:PSG) Forecasts Dramatically
Feb 16
We Think PharmaSGP Holding's (ETR:PSG) Statutory Profit Might Understate Its Earnings Potential
Jan 26Do Institutions Own PharmaSGP Holding SE (ETR:PSG) Shares?
Dec 04Shareholder Returns
| PSG | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -0.3% | -6.7% | 1.9% |
| 1Y | -26.7% | -26.5% | 5.7% |
Return vs Industry: PSG matched the German Pharmaceuticals industry which returned -26.5% over the past year.
Return vs Market: PSG underperformed the German Market which returned 5.7% over the past year.
Price Volatility
| PSG volatility | |
|---|---|
| PSG Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 9.4% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: PSG is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: PSG's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 85 | Natalie Weigand | https://pharmasgp.com |
PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany. The company’s pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream for the treatment of different pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Revitensin, a drug for treatment of hair loss; Dorisol, a pain relies tablet; Fulminan, a beauty drink; Lindaven, a pharmaceutical drops to treat their unpleasant problem; and SCLEROCALMAN, a drug for the treatment of clogged cerebral blood vessels. It also offers Prostacalman, a medication for cystitis and urination discomfort in a benign enlarged prostate; Revoten, for women with weak connective tissue; Mindalin, a micronutrient drink for a healthy cardiovascular system; MELISTON, a prescription-free tablets to treat anxiety, restlessness and mood swings; Deruba, a cream for skin redness; Lentisol prevents the formation of new pigment spots; Neodolor, a headache tablet; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo.
PharmaSGP Holding SE Fundamentals Summary
| PSG fundamental statistics | |
|---|---|
| Market Cap | €224.40m |
| Earnings (TTM) | €14.99m |
| Revenue (TTM) | €97.55m |
15.0x
P/E Ratio2.3x
P/S RatioIs PSG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PSG income statement (TTM) | |
|---|---|
| Revenue | €97.55m |
| Cost of Revenue | €9.16m |
| Gross Profit | €88.40m |
| Other Expenses | €73.41m |
| Earnings | €14.99m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.25 |
| Gross Margin | 90.61% |
| Net Profit Margin | 15.37% |
| Debt/Equity Ratio | 210.6% |
How did PSG perform over the long term?
See historical performance and comparison